| Improving chimeric antigen receptor-modified T cell function by reversing the immunosuppressive tumor microenvironment of pancreatic cancer S Mohammed, S Sukumaran, P Bajgain, N Watanabe, HE Heslop, ... Molecular therapy 25 (1), 249-258, 2017 | 268 | 2017 |
| Armed oncolytic adenovirus–expressing PD-L1 mini-body enhances antitumor effects of chimeric antigen receptor T cells in solid tumors K Tanoue, A Rosewell Shaw, N Watanabe, C Porter, B Rana, ... Cancer research 77 (8), 2040-2051, 2017 | 204 | 2017 |
| Fine-tuning the CAR spacer improves T-cell potency N Watanabe, P Bajgain, S Sukumaran, S Ansari, HE Heslop, CM Rooney, ... Oncoimmunology 5 (12), e1253656, 2016 | 190 | 2016 |
| Adenovirotherapy delivering cytokine and checkpoint inhibitor augments CAR T cells against metastatic head and neck cancer AR Shaw, CE Porter, N Watanabe, K Tanoue, A Sikora, S Gottschalk, ... Molecular Therapy 25 (11), 2440-2451, 2017 | 185 | 2017 |
| Reversal of tumor immune inhibition using a chimeric cytokine receptor AM Leen, S Sukumaran, N Watanabe, S Mohammed, J Keirnan, ... Molecular Therapy 22 (6), 1211-1220, 2014 | 177 | 2014 |
| Enhancing the potency and specificity of engineered T cells for cancer treatment S Sukumaran, N Watanabe, P Bajgain, K Raja, S Mohammed, WE Fisher, ... Cancer discovery 8 (8), 972-987, 2018 | 117 | 2018 |
| CAR T cell therapy for breast cancer: harnessing the tumor milieu to drive T cell activation P Bajgain, S Tawinwung, L D’Elia, S Sukumaran, N Watanabe, V Hoyos, ... Journal for immunotherapy of cancer 6, 1-13, 2018 | 103 | 2018 |
| Engineered off-the-shelf therapeutic T cells resist host immune rejection F Mo, N Watanabe, MK McKenna, MJ Hicks, M Srinivasan, D Gomes-Silva, ... Nature biotechnology 39 (1), 56-63, 2021 | 98 | 2021 |
| Alteration of POLDIP3 Splicing Associated with Loss of Function of TDP-43 in Tissues Affected with ALS A Shiga, T Ishihara, A Miyashita, M Kuwabara, T Kato, N Watanabe, ... Public Library of Science 7 (8), e43120, 2012 | 96 | 2012 |
| Impact of manufacturing procedures on CAR T cell functionality N Watanabe, F Mo, MK McKenna Frontiers in immunology 13, 876339, 2022 | 77 | 2022 |
| Clinical CAR-T cell and oncolytic virotherapy for cancer treatment N Watanabe, MK McKenna, AR Shaw, M Suzuki Molecular therapy 29 (2), 505-520, 2021 | 60 | 2021 |
| A leukemic plasmacytoid dendritic cell line, PMDC05, with the ability to secrete IFN-α by stimulation via Toll-like receptors and present antigens to naïve T cells M Narita, N Watanabe, A Yamahira, S Hashimoto, N Tochiki, A Saitoh, ... Leukemia research 33 (9), 1224-1232, 2009 | 52 | 2009 |
| Anti-tumor cytotoxicity of γδ T cells expanded from peripheral blood cells of patients with myeloma and lymphoma A Saitoh, M Narita, N Watanabe, N Tochiki, N Satoh, J Takizawa, ... Medical oncology 25, 137-147, 2008 | 50 | 2008 |
| Selectively targeting myeloid-derived suppressor cells through TRAIL receptor 2 to enhance the efficacy of CAR T cell therapy for treatment of breast cancer SA Nalawade, P Shafer, P Bajgain, MK McKenna, A Ali, L Kelly, J Joubert, ... Journal for immunotherapy of cancer 9 (11), 2021 | 46 | 2021 |
| WT1 peptide vaccination in combination with imatinib therapy for a patient with CML in the chronic phase M Narita, M Masuko, T Kurasaki, T Kitajima, S Takenouchi, A Saitoh, ... International journal of medical sciences 7 (2), 72, 2010 | 45 | 2010 |
| Modulating TNFα activity allows transgenic IL15-Expressing CLL-1 CAR T cells to safely eliminate acute myeloid leukemia PA Atilla, MK McKenna, H Tashiro, M Srinivasan, F Mo, N Watanabe, ... Journal for immunotherapy of cancer 8 (2), 2020 | 39 | 2020 |
| Feasibility and preclinical efficacy of CD7-unedited CD7 CAR T cells for T cell malignancies N Watanabe, F Mo, R Zheng, R Ma, VC Bray, DG van Leeuwen, ... Molecular Therapy 31 (1), 24-34, 2023 | 36 | 2023 |
| Expanding CAR T cells in human platelet lysate renders T cells with in vivo longevity A Torres Chavez, MK McKenna, E Canestrari, CT Dann, CA Ramos, ... Journal for immunotherapy of cancer 7, 1-15, 2019 | 32 | 2019 |
| Kinetics of pDCs, mDCs, γδT cells and regulatory T cells in association with graft versus host disease after hematopoietic stem cell transplantation N Watanabe, M Narita, T Furukawa, T Nakamura, A Yamahira, M Masuko, ... International journal of laboratory hematology 33 (4), 378-390, 2011 | 32 | 2011 |
| Type I IFN-mediated enhancement of anti-leukemic cytotoxicity of γδ T cells expanded from peripheral blood cells by stimulation with zoledronate N Watanabe, M Narita, A Yokoyama, A Sekiguchi, A Saito, N Tochiki, ... Cytotherapy 8 (2), 118-129, 2006 | 31 | 2006 |
